GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sanara MedTech Inc (NAS:SMTI) » Definitions » Cyclically Adjusted Revenue per Share

Sanara MedTech (Sanara MedTech) Cyclically Adjusted Revenue per Share : $0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sanara MedTech Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sanara MedTech's adjusted revenue per share for the three months ended in Mar. 2024 was $2.202. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Sanara MedTech's average Cyclically Adjusted Revenue Growth Rate was 13.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Sanara MedTech was 11.80% per year. The lowest was 5.60% per year. And the median was 9.30% per year.

As of today (2024-05-16), Sanara MedTech's current stock price is $31.70. Sanara MedTech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.00. Sanara MedTech's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sanara MedTech was 12.08. The lowest was 0.71. And the median was 3.41.


Sanara MedTech Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sanara MedTech's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanara MedTech Cyclically Adjusted Revenue per Share Chart

Sanara MedTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.15 4.17 4.28 4.89 5.56

Sanara MedTech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.10 5.28 5.44 5.56 -

Competitive Comparison of Sanara MedTech's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, Sanara MedTech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanara MedTech's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sanara MedTech's Cyclically Adjusted PS Ratio falls into.



Sanara MedTech Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sanara MedTech's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.202/131.7762*131.7762
=2.202

Current CPI (Mar. 2024) = 131.7762.

Sanara MedTech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.620 100.560 0.812
201409 0.764 100.428 1.002
201412 0.690 99.070 0.918
201503 0.954 99.621 1.262
201506 0.701 100.684 0.917
201509 0.844 100.392 1.108
201512 0.659 99.792 0.870
201603 1.010 100.470 1.325
201606 1.159 101.688 1.502
201609 1.300 101.861 1.682
201612 1.591 101.863 2.058
201703 0.774 102.862 0.992
201706 1.298 103.349 1.655
201709 1.393 104.136 1.763
201712 1.491 104.011 1.889
201803 1.235 105.290 1.546
201806 0.956 106.317 1.185
201809 0.662 106.507 0.819
201812 0.020 105.998 0.025
201903 5.907 107.251 7.258
201906 1.275 108.070 1.555
201909 1.230 108.329 1.496
201912 0.939 108.420 1.141
202003 0.568 108.902 0.687
202006 0.478 108.767 0.579
202009 0.686 109.815 0.823
202012 0.761 109.897 0.913
202103 0.735 111.754 0.867
202106 0.837 114.631 0.962
202109 0.775 115.734 0.882
202112 0.934 117.630 1.046
202203 1.027 121.301 1.116
202206 1.185 125.017 1.249
202209 1.609 125.227 1.693
202212 1.887 125.222 1.986
202303 1.899 127.348 1.965
202306 1.915 128.729 1.960
202309 1.923 129.860 1.951
202312 2.110 129.419 2.148
202403 2.202 131.776 2.202

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sanara MedTech  (NAS:SMTI) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sanara MedTech was 12.08. The lowest was 0.71. And the median was 3.41.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sanara MedTech Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sanara MedTech's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanara MedTech (Sanara MedTech) Business Description

Traded in Other Exchanges
N/A
Address
1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser and BIAKOS Skin and Wound Gel.
Executives
Eric D Major director 751 MILLER DRIVE SE, LEESBURG VA 20175
Zachary B. Fleming officer: President - Surgical Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Shawn M. Bowman officer: President - Wound Care Div. 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Rebecca E Mcmahon officer: President - R&D 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Sara N Ortwein director 5959 LAS COLINAS BOULEVARD, IRVING TX 75039-2298
Robert Andrew Desutter director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Eric D Tanzberger director 1929 ALLEN PARKWAY, HOUSTON TX 77219
Christopher A. Morrison officer: President - Telehealth Svcs. 1200 SUMMIT AVENUE, SUITE 414, FORT WORTH TX 76102
Roszell Iii Mack director 1200 SUMMIT AVE, SUITE 414, FORT WORTH TX 76102
Cgi Cellerate Rx, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Catalyst Rochal, Llc 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
Bradley J. Gurasich 10 percent owner C/O THE CATALYST GROUP, INC., 7500 RIALTO BLVD., BLDG. II, SUITE 220, AUSTIN TX 78735
J Michael Carmena director, officer: Principal Executive Officer 1200 SUMMIT AVE STE 414, FORT WORTH TX 76102
Michael D. Mcneil officer: Chief Financial Officer 1200 SUMMIT AVE, STE 414, FORT WORTH TX 76102
Catalyst Group, Inc. 10 percent owner 1375 ENCLAVE PARKWAY, HOUSTON TX 77077

Sanara MedTech (Sanara MedTech) Headlines

From GuruFocus

Sanara MedTech to Participate in Two Upcoming Healthcare Conferences

By Value_Insider Value_Insider 11-21-2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 07-05-2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-05-2022

Sanara MedTech Inc. Announces First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 05-16-2022

Sanara MedTech Inc. Announces Second Quarter 2022 Results

By PurpleRose PurpleRose 08-15-2022

Sanara MedTech Inc. Announces First Quarter 2023 Results

By sperokesalga sperokesalga 05-15-2023

Sanara MedTech and InfuSystem Announce Wound Therapy Partnership

By Value_Insider Value_Insider 11-03-2022